Home

Novel luciferase reporter provides optimal performance in high-throughput screens of G-protein-coupled agonist binding.Background: G-protein-coupled receptors (GPCRs) constitute the largest class of cell surface receptors. GPCR genes account for 5% of the human genome. GPCRs also represent the largest and among the most efficacious classes of therapeutic targets for diseases including cardiovascular disease, cancer, and asthma. Technology Overview:  The novel cyclic adenosine monophosphate (cAMP)-responsive luciferase  reporter exhibits optimal performance in high-throughput screens of agonist binding at GPCRs. This reporter exhibits substantially reduced basal activity, a feature that is likely to be of particular importance when performing high-throughput screens in which false-positive hits are to be avoided. Compared to other reporters, the present construct affords a much wider dynamic range of activation (>340 fold-stimulation) upon exposure to GPCR agonists with cAMP signaling properties. https://suny.technologypublisher.com/files/sites/2009-110.jpghttps://www.pexels.com/photo/scientist-in-laboratory-3735769/ Advantages:  

• Significantly reduced basal luciferase activity inherent to similar reporters.
• Wide dynamic range of activation upon exposure to agonist.

• Research tool
• Drug candidate high-throughput screening

An adapter that expedites bone surgery by making hand-held retractors self-retaining.  Background: Orthopedic surgeons require unfettered access to exposed bone. That means keeping the skin, subcutaneous fat, tissues, and muscles out of the way with retractors. Currently, there are two common types of retractors for this purpose—self-retaining retractors, which stay open on their own, and hand-held retractors, which need an assistant to hold them. The current disclosure describes an adapter that couples the hand-held retractors to the self-retaining retractor, enabling the hand-held retractors to be self-retaining. This eliminates the need for an assistant and affords the surgeon better exposure to the bone, thereby increasing the efficiency of surgery while reducing cost. Technology Overview:  The device combines the functions of a hand-held retractor, used on soft tissue near the bone, with those of a self-retaining retractor, used on surface levels like skin and subcutaneous fat. The device consists of two sleeves slipped over the arms of the hand-held retractors. The inner surfaces of the sleeves have inverted V-shaped projections to capture the tips of the self-retaining retractor. When the tips are inserted into the projections on the sleeves, the self-retaining retractor secures the hand-held retractors and keeps them open. The adapter can be used with equipment that is readily available in every orthopedic operating room. It will be made of sterilizable metal or durable plastic to guarantee years of use.   https://suny.technologypublisher.com/files/sites/110-20302.jpg Advantages:

• Increases efficiency of surgery.
• Reduces costs.

­Combined drill guide and suture passer for use in assisting repair following posterior approach total hip arthroplasty. Background:
The posterior approach to the hip for total hip replacement as well as trauma, pediatric orthopedic surgery, and tumors is the most common approach for total hip arthroplasties. However, the performance of this surgery carries risks given the lack of a devoted and standardized instrument to assist in repairing the soft tissues over the hip joint before closure, leaving room for mistakes given that the repair is operator dependent.Technology Overview:  
Upstate Medical University Orthopedic Surgeons have designed a device that features a drill guide and suture passer for posterior approach total hip arthroplasty. The device will facilitate hole drilling, as well as passing and tying sutures over the desired tissues. This will eliminate the need to visually decide where to place the drill to make the holes, as well as manually passing the suture passer through the holes to repair the tissues of the surgery for a faster, more precise, and easier procedure, which could reduce the total time of surgery, minimize risk of posterior hip dislocation and may decrease patient recovery time. https://suny.technologypublisher.com/files/sites/adobestock_272951884_(1).jpeg Advantages:  •    Sterilizable metallic surgical instrument for repetitive use.
•    Less variability of results due to user experience level.
•    Expedites closure process, minimizing post-operative risks.Intellectual Property Summary:
Patent Pending US 18/236,641Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.
 

Provides new pathways for biomarkers and drug discovery for cancer patients.  Background:
The gene Abelson interactor protein-1 (ABI1) encodes a member of the Abelson-interactor family of adaptor proteins. These proteins facilitate signal transduction as components of several multiprotein complexes, and regulate actin polymerization and cytoskeletal remodeling through interactions with Abelson tyrosine kinases. The androgen receptor (AR) protein functions as a steroid-hormone activated transcription factor. ABI1 and AR are widely expressed in human tissues. Many cancers show sex-specific tumorigenesis, tumor progression, and sensitivity to hormonal drugs. The ABI1-AR axis might play critical roles in these tissue and drug sensitivities and toxicities. For example, ABI1 regulates a specific subset of genes associated with prostate tumor progression. These genes are biomarkers and potential targets of tumor progression.
Technology Overview:  
This technology defines ABI1-AR reciprocal regulation involving two non-exclusive molecular mechanisms of ABI1-AR and ABI1-DNA interactions. ABI1-DNA binding activity predicts survival of prostate cancer patients. ABI1 binds AR via a multivalent interaction. The ABI1-AR transcriptional program is altered during tumor progression and by anti-androgen treatments, suggesting that ABI1 is a key plasticity regulator in PCa by coupling its actin regulatory and signaling functions to transcriptional regulation. ABI1-AR reciprocal regulation has far reaching implications for tumor plasticity and androgen-sensitive pathogenesis. These interactions are co-regulated during PCa evolution and clinical treatment promoting tumor plasticity and progression. This provides new paths for biomarker and drug design discovery in PCa. https://suny.technologypublisher.com/files/sites/adobestock_282277912.jpegAdvantages:  
•    Provides a novel mechanism for predicting survival rates among cancer patients.
•    May enable drug discovery for a wide variety of cancers. Applications:  
The primary applications for this technology are the development of biomarkers for assessing cancer patient survival rates, and drug discovery.  Intellectual Property Summary: US Provisional Patent Application Ser. No. 63/463,457, filed May 2, 2023. Stage of Development:
TRL 3 - Experimental proof of concept Licensing Status:
This technology is available for licensing.Licensing Potential:
This technology would be of interest to anyone involved in the development of biomarkers and/or therapeutics for cancer, including:
•    Pharmaceutical companies.
•    Hospitals.
•    Medical research laboratories.
•    Universities.